PATENT CLAIM ANALYSIS

Application Number: 16065932
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "001000"]

Abstract:
Some embodiments are directed to a substance that inhibits P2Y12 receptor for use in the preventive treatment of systemic sclerosis in patients with Raynaud's phenomenon and a dysimmunity.

Claim (Index 9):
The substance for use according to  claim 1 , wherein the substance is hydrogen sulphate clopidogrel.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.07143
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13939058', '13503339', '14207246', '10966845', '15385705']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7425509818306072
- 35 USC 102 Novelty (BERT): 0.5213148181946703
- Combined Prediction Score: 0.7204273654670135
- Mean Citation Score: 235.36269
- Max Citation Score: 238.25818
- Similarity Product: 136.41564374773503

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test